Independent and combined effects of very low nicotine cigarette messages and e-cigarette messages: a randomised clinical trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Who Took Part

According to the abstract, 971 adults were involved.

By PubMed's age tags, the people studied were teenagers, young adults and adults, both men and women.

In 2022-2023, the researchers conducted a four-group randomised clinical trial with a national probability sample from an online panel (971 adults who smoked cigarettes exclusively, 472 adults who dual used cigarettes and e-cigarettes and 458 adults aged 18-29 who had never smoked).

Participants were randomised (parallel assignment) to one message condition: (1) VLNCs as harmful but easier to quit than regular cigarettes (n=468), (2) those who are not ready to quit should consider switching to e-cigarettes as less harmful alternatives (n=484), (3) combined (VLNC and e-cigarette messages; n=476) or (4) control condition (ie, water ads), n=473.

How the Study Was Run

The design is described as randomized and parallel-group.

The adults were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Groups ran in parallel: each of the adults stayed in one arm throughout.

The primary outcome was perceived absolute harm of VLNCs.

What Was Measured

Topics PubMed links to this paper include Electronic Nicotine Delivery Systems, Smoking Cessation, Tobacco Products, Nicotine, Vaping and Cigarette Smoking.

The authors tagged it with the keywords Addiction and Electronic nicotine delivery devices.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Therapeutic nicotine (patch, non-peptide) in 971 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Tobacco control), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.